Valuation Picture: Premium Amidst Sector Parity
The current P/E of 37.65 places Sun Pharmaceutical Industries Ltd at a 4.5% premium to the Pharmaceuticals & Biotechnology industry average of 36.04. This premium suggests that investors are willing to pay slightly more for the company’s earnings relative to its peers, reflecting confidence in its earnings stability or growth prospects. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. Sun Pharma’s market capitalisation of ₹4,66,106.81 crores further cements its status as a large-cap stalwart within the sector.
Performance Across Timeframes: A Mixed Momentum Story
Examining returns across multiple timeframes reveals a compelling divergence. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 14.77% gain, significantly outperforming the Sensex’s 5.45% loss. This outperformance extends to longer horizons as well, with three-year and five-year returns of 76.95% and 187.01% respectively, dwarfing the Sensex’s 16.55% and 48.90% gains over the same periods.
In contrast, the short-term picture is more volatile. The stock’s one-month return of 5.74% and three-month return of 16.66% remain positive and well ahead of the Sensex, which declined by 1.96% over three months. However, the most recent trading day saw a 0.70% decline, slightly underperforming the Sensex’s flat 0.02% movement. The stock has been on a two-day consecutive gain streak, rising 1.31% in that period, indicating some short-term resilience despite the latest dip. Sun Pharma’s year-to-date return of 12.96% also contrasts sharply with the Sensex’s 8.80% loss, underscoring its relative strength in 2026.
Moving Average Configuration: Bullish Across All Key Levels
The technical setup for Sun Pharmaceutical Industries Ltd is notably constructive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward momentum across both short and long-term horizons. This configuration typically indicates a sustained bullish trend, with the stock maintaining support at multiple key technical levels. The proximity to its 52-week high—just 0.2% away from ₹1962.5—further reinforces this positive technical stance. Sun Pharma’s ability to hold above these averages suggests that recent gains are supported by underlying strength rather than a transient rally, but is this momentum sustainable or a prelude to consolidation?
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Sector Performance Context: Flat Results Amidst Stability
The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Among two stocks that declared results, none reported positive surprises, with both delivering flat outcomes. This environment of muted sector performance contrasts with Sun Pharmaceutical Industries Ltd’s relative outperformance, highlighting its resilience. The sector’s overall stability may be providing a steady backdrop, but does this set the stage for a divergence in stock-specific fortunes?
Rating Reassessment: Previously Rated Hold
On 8 June 2026, Sun Pharmaceutical Industries Ltd’s rating was updated from Hold, reflecting a reassessment of its fundamentals and market position. The company’s Mojo Score of 72.0 remains robust, signalling a strong overall profile. This rating change comes amid the stock’s solid performance across multiple timeframes and its premium valuation relative to the industry. What is the current rating, and how does it align with the stock’s valuation and technical setup?
Want to dive deeper on Sun Pharmaceutical Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Collective Data Insights: Valuation, Momentum, and Technical Strength
Bringing together the valuation, performance, and technical data, Sun Pharmaceutical Industries Ltd presents a picture of a large-cap pharmaceutical leader trading at a slight premium to its sector. Its consistent outperformance over one, three, and five years contrasts with the sector’s flat earnings results, underscoring company-specific strengths. The bullish moving average configuration and proximity to a 52-week high reinforce the technical momentum, even as short-term fluctuations persist. Should investors in Sun Pharma hold, buy more, or reconsider? The current rating provides the answer.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
